Navigation Links
Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
Date:10/26/2010

NEW YORK, Oct. 26 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals (Nasdaq: KERX) reported today the randomization of the last patient in its short-term study component of its Phase 3 registration program of Zerenex™ (ferric citrate), the Company's iron-based phosphate binder for the treatment of elevated serum phosphorous levels, or hyperphosphatemia, in patients with end-stage renal disease on dialysis.  The Zerenex Phase 3 clinical program is being conducted pursuant to a Special Protocol Assessment (SPA) with the Food and Drug Administration (FDA). The Company expects to complete the study and report top-line data before the end of the year.

The Zerenex Phase 3 short-term efficacy study is a multicenter, randomized, open-label clinical trial being conducted at 14 centers in the United States.  Approximately 150 patients have completed the 2-week washout period and have been randomized 1:1:1 to receive a fixed dose of Zerenex (1 gram, 6 grams or 8 grams per day) for a treatment period of 28 days.  The primary endpoint of the study is to demonstrate a dose response in the change of serum phosphorous from baseline (end of washout period) to end of the treatment period (day 28).

Dr. Julia Lewis, Professor of Medicine, Department of Nephrology, Vanderbilt University School of Medicine, and member of the Executive Committee of the Collaborative Study Group, is the Study Chair of the Zerenex Phase 3 registration program.  Dr. Samuel S. Blumenthal, Professor of Medicine at Medical College of Wisconsin, is the study's Co-Principal Investigator.

Ron Bentsur, Chief Executive Officer of Keryx, commented, "We are pleased by the rate of enrollment into this study, and we are grateful for the efficiency and dedication demonstrated by our clinical investigators.  We look forward to announcing the top-line data from this study before year-e
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at BioCenturys NewsMakers in the Biotech Industry Conference
2. Keryx Biopharmaceuticals to Present at JMP Securities Healthcare Conference
3. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
4. Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. Keryx Receives FDA Fast Track Designation for KRX-0401 (Perifosine) for the Treatment of Relapsed/Refractory Multiple Myeloma
7. Keryx Biopharmaceuticals to Present at the Piper Jaffray 21st Annual Health Care Conference
8. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
9. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
10. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
11. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... -- Victoria Vein & Surgery Clinic is the only clinic offering ... Victoria, Texas . The clinic specializes in ... treatments for a variety of medical and cosmetic conditions. High-end ... services for their patients. Since adding laser tattoo removal, Victoria ... residents get rid of their unwanted ink. ...
(Date:3/27/2015)... YORK , March 27, 2015 A new ... Latin America – Chile ... are top targets for IVD firms.  The healthcare ... figures heavily into IVD strategies for the Latin American continent ... to support globally distributed supply operations. However, the country,s regional ...
(Date:3/27/2015)... CAMBRIDGE, Mass. , March 27, 2015 /PRNewswire/ ... unique platform for drug discovery and development services ... assays for the pharmaceutical industry, announced financial results ... Timothy C.  Tyson, Chairman of XRpro ... steps to successfully transition from development stage to ...
Breaking Medicine Technology:Victoria Vein And Surgery Clinic Uses Advanced Astanza Duality Tattoo Removal Technology 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4
... Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to... -- DALLAS, September 6, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... function(data) { var s = ,; var first_result; // Results are keyed by longUrl, so we need ...
... The editors of Inc. Magazine have included Qosina Corporation, ... 5000" List , which acknowledges the top 5,000 fastest ... being recognized for the second consecutive year on the ... the "Inc. 500" in 1989 and "Inc. 5000" in ...
Cached Medicine Technology:Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 2Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 3Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 4Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 5Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 6Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 7Diagnostic Imaging Market to 2016 - Nuclear Imaging Systems and Ultrasound Systems to be the key Revenue Generators now Available at ReportsandReports 8Qosina Recognized for Second Consecutive Year on the 'Inc. 5000' List 2
(Date:3/28/2015)... How best to treat and recover from ... medicine. While diagnostic hip injections are commonly performed for ... research presented today at the American Orthopaedic Society for ... pain relief from this diagnostic injection may not predict ... study looked to assess if the amount of pain ...
(Date:3/28/2015)... OR (PRWEB) March 28, 2015 Lately ... the media regarding recent changes and proposals around the ... , current and former collegiate student-athletes across a spectrum ... and reflect on common challenges. The special panel consists ... country in sports ranging from football, track and field, ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 ARDX will sponsor ... from 12pm -3pm at the Chesapeake Conference Center in Chesapeake, ... sponsoring an empowering event for women in the Hampton Roads ... the Stories of Women’s Lives. Women grow stronger through ... each other. This year the WWC™ theme is T-talk ...
(Date:3/27/2015)... Long Island, NY (PRWEB) March 27, 2015 ... objective, cancer-focused training and business criteria for the spa ... and services to clients who have experienced or are ... of the global Spafinder Wellness 365® Network, will be ... Spafinder.com and recognized as a provider of safe, therapeutic ...
(Date:3/27/2015)... Mo (PRWEB) March 27, 2015 ... for patients undergoing percutaneous coronary intervention (PCI), resulting ... have observed a “risk-treatment paradox,” in which the ... from treatment are treated less often with bleeding ... at Saint Luke’s Mid America Heart Institute asked ...
Breaking Medicine News(10 mins):Health News:Pain Injections for Hip Arthroscopy Patients May Not Predict Surgical Outcomes 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 2Health News:SCI TV Panel of Former College Athletes Discusses Student Athlete Experience 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 3Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Certified as “Cancer Aware” by Wellness for Cancer and Recognized on Spafinder.com 4Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 2Health News:Precision Medicine Improves Use of Bleeding Avoidance Strategies and Reduces Bleeding in Patients Undergoing Percutaneous Coronary Intervention 3
... ... don,t need the pretty bottles or sweet aroma of fragrant lotions and cleansers-men ... tailored specifically to a man,s needs without added synthetic ingredients that may be ... uses the purity of nature to enhance the skin,s surface and makes a ...
... ... Drive in Beverly Hills to Main Street in small towns across America. The medical community ... growing epidemic. , ... PA (PRWEB) June 1, 2010 -- Nearly 7 million Americans are abusing prescription drugs – ...
... ... Harmful Bacteria, Including MRSA. Jan-Pro, Global Leader in Commercial Cleaning, Once Again Leads the ... Offer Powerful New Solution in the control of infectious microorganisms - EnviroShield Disinfectant Technology ... (PRWEB) June ...
... ... of a novel combination of two FDA Approved topical medications. This triple blind controlled ... ... Oscar Klein M.D. today announced the results of a triple blind hair loss research study ...
... ... a brand new buy back plan. , ... (PRWEB) – CosmeticLaserWorld.com ( www.cosmeticlaserworld.com ), a market leader in ... should purchase equipment from the reseller. Under an Investment Protection Plan, the company will ...
... - Shionogi Pharma, Inc., a U.S.-based group company of ... results of two pivotal studies of the investigational new ... for the treatment of primary premature ejaculation (PE). These ... (AUA) Annual Meeting in San Francisco. Evaluating a ...
Cached Medicine News:Health News:Garden of Eve Launches a Father's Day Tribute for Men Who Want to Look Well-groomed with Little Fuss 2Health News:Garden of Eve Launches a Father's Day Tribute for Men Who Want to Look Well-groomed with Little Fuss 3Health News:Garden of Eve Launches a Father's Day Tribute for Men Who Want to Look Well-groomed with Little Fuss 4Health News:Medical Community Responds to Prescription Drug Abuse 2Health News:Medical Community Responds to Prescription Drug Abuse 3Health News:JAN-PRO Launches Exclusive “EnviroShield™” Disinfecting System - Kills Harmful Bacteria, Including MRSA 2Health News:JAN-PRO Launches Exclusive “EnviroShield™” Disinfecting System - Kills Harmful Bacteria, Including MRSA 3Health News:Hair Loss Research Study Reveals Important Breakthrough in the Treatment of Male Pattern Baldness 2Health News:Hair Loss Research Study Reveals Important Breakthrough in the Treatment of Male Pattern Baldness 3Health News:CosmeticLaserWorld.com Gives Buyers Peace of Mind Through Industry-Leading Investment Protection Plan 2Health News:Pivotal data for the investigational treatment PSD502 for primary premature ejaculation 2Health News:Pivotal data for the investigational treatment PSD502 for primary premature ejaculation 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: